Protalix BioTherapeutics (PLX) Receivables - Net (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Receivables - Net of $2.9 million for Q1 2026, down 37.13% year-over-year from $4.7 million in Q1 2025, and down 66.75% quarter-over-quarter from $8.8 million in Q4 2025.
Protalix BioTherapeutics (PLX) Receivables - Net (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Receivables - Net history runs 17 years deep, the most recent figure standing at $2.9 million for Q1 2026.
- In Q1 2026, Receivables - Net fell 37.13% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $2.9 million (down 37.13% YoY), while the FY2025 annual figure was $8.8 million, up 203.88% from the prior year.
- Receivables - Net for Q1 2026 stood at $2.9 million, down from $8.8 million in the prior quarter.
- The five-year high for Receivables - Net was $14.4 million in Q3 2025, with the low at $1.3 million in Q1 2023.
- The 5-year median for Receivables - Net is $4.7 million (2025), against an average of $5.9 million.
- The sharpest annual moves came in 2023 and 2025: Receivables - Net sank 77.93% in 2023, then jumped 557.18% in 2025.
- Protalix BioTherapeutics' Receivables - Net stood at $4.6 million in 2022, then grew by 14.96% to $5.3 million in 2023, then sank by 44.82% to $2.9 million in 2024, then jumped by 203.88% to $8.8 million in 2025, then tumbled by 66.75% to $2.9 million in 2026.
- Business Quant data shows PLX's Receivables - Net at $2.9 million in Q1 2026, $8.8 million in Q4 2025, and $14.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.50 Mn |
| Jun 30, 2026 | 16.50 Mn |
| Mar 31, 2026 | 2.94 Mn |
| Mar 31, 2026 | 2.94 Mn |
| Dec 31, 2025 | 8.84 Mn |
| Dec 31, 2025 | 8.84 Mn |
| Sep 30, 2025 | 14.43 Mn |
| Sep 30, 2025 | 14.43 Mn |
| Jun 30, 2025 | 9.44 Mn |
| Jun 30, 2025 | 9.44 Mn |
| Mar 31, 2025 | 4.68 Mn |
| Mar 31, 2025 | 4.68 Mn |
| Dec 31, 2024 | 2.91 Mn |
| Dec 31, 2024 | 2.91 Mn |
| Sep 30, 2024 | 2.20 Mn |
| Sep 30, 2024 | 2.20 Mn |
| Jun 30, 2024 | 10.13 Mn |
| Jun 30, 2024 | 10.13 Mn |
| Mar 31, 2024 | 3.76 Mn |
| Mar 31, 2024 | 3.76 Mn |